Screening of Benzimidazole-Based Anthelmintics and Their Enantiomers as Repurposed Drug Candidates in Cancer Therapy

Target Inhibition of CBP Induced Cell Senescence in BCR-ABL- T315I Mutant Chronic Myeloid Leukemia

(2021) Ke Yang et al.   Frontiers in Oncology

New drugs are not enough‑drug repositioning in oncology: An update

(2020) Romina Armando et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Integrative proteomic and functional analyses provide novel insights into the action of the repurposed drug candidate nitroxoline in AsPC-1 cells

(2020) Serena Veschi et al.   Scientific Reports

Repositioning of Anthelmintic Drugs for the Treatment of Cancers of the Digestive System

(2020) Federica Laudisi et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Thiabendazole and Thiabendazole-Formic Acid Solvate: A Computational, Crystallographic, Spectroscopic and Thermal Study

(2020) Andreia M. Tabanez et al.   MOLECULES

Efficacy of novel albendazole salt formulations against secondary cystic echinococcosis in experimentally infected mice

(2020) G. Vural et al.   PARASITOLOGY

Preparation and Evaluation of Mebendazole Microemulsion for Intranasal Delivery: an Alternative Approach for Glioblastoma Treatment

(2020) Julio Mena-Hernández et al.   AAPS PHARMSCITECH

Drug repurposing and relabeling for cancer therapy: Emerging benzimidazole antihelminthics with potent anticancer effects

(2020) Joyobrato Nath et al.   LIFE SCIENCES

SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules

(2019) Antoine Daina et al.   NUCLEIC ACIDS RESEARCH

Synthesis of novel benzothiazole amides: Evaluation of PPAR activity and anti-proliferative effects in paraganglioma, pancreatic and colorectal cancer cell lines

(2019) Alessandra Ammazzalorso et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature

(2019) Guerini et al.   Cancers

The Benzimidazole-Based Anthelmintic Parbendazole: A Repurposed Drug Candidate That Synergizes with Gemcitabine in Pancreatic Cancer

(2019) Rosalba Florio et al.   Cancers

Mebendazole exhibits potent anti-leukemia activity on acute myeloid leukemia

(2018) Licai He et al.   EXPERIMENTAL CELL RESEARCH

N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs

(2018) Sarah C. Zimmermann et al.   JOURNAL OF MEDICINAL CHEMISTRY

Flubendazole induces mitotic catastrophe and apoptosis in melanoma cells

(2018) K. Čáňová et al.   TOXICOLOGY IN VITRO

Repositioning of Anti-parasitic Drugs in Cyclodextrin Inclusion Complexes for Treatment of Triple-Negative Breast Cancer

(2018) Josefina Priotti et al.   AAPS PHARMSCITECH

Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells

(2018) Serena Veschi et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

A chromatographic study on the retention behavior of the amylose tris(3-chloro-5-methylphenylcarbamate) chiral stationary phase under aqueous conditions

(2018) Roberto Cirilli et al.   JOURNAL OF SEPARATION SCIENCE

Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways

(2018) Nilambra Dogra et al.   Scientific Reports

The sodium salt of the enantiomers of ricobendazole: Preparation, solubility and chiroptical properties

(2017) Roberto Cirilli et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Effects of PPARα inhibition in head and neck paraganglioma cells

(2017) Rosalba Florio et al.   PLoS One

SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules

(2017) Antoine Daina et al.   Scientific Reports

Flubendazole induces mitotic catastrophe and senescence in colon cancer cellsin vitro

(2016) Věra Králová et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Albendazole as a promising molecule for tumor control

(2016) L.S.E.P.W. Castro et al.   Redox Biology

A Review of Pharmacokinetic Drug–Drug Interactions with the Anthelmintic Medications Albendazole and Mebendazole

(2015) Shane Ashley Pawluk et al.   CLINICAL PHARMACOKINETICS

Potential Anti-cancer Drugs Commonly Used for Other Indications

(2015) Veronika Hanusova et al.   CURRENT CANCER DRUG TARGETS

Drug repurposing in oncology—patient and health systems opportunities

(2015) Francesco Bertolini et al.   Nature Reviews Clinical Oncology

Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells

(2015) Zhi-Jie Hou et al.   Oncotarget

Recent Advances in Drug Repositioning for the Discovery of New Anticancer Drugs

(2014) Joong Sup Shim et al.   International Journal of Biological Sciences

Repurposing the Antihelmintic Mebendazole as a Hedgehog Inhibitor

(2014) A. R. Larsen et al.   MOLECULAR CANCER THERAPEUTICS

Drug Resistance in Cancer: An Overview

(2014) Genevieve Housman et al.   Cancers

Integrative genetic, epigenetic and pathological analysis of paraganglioma reveals complex dysregulation of NOTCH signaling

(2013) Alessandro Cama et al.   ACTA NEUROPATHOLOGICA

Effect of the water content on the retention and enantioselectivity of albendazole and fenbendazole sulfoxides using amylose-based chiral stationary phases in organic–aqueous conditions

(2013) Sabrina Materazzo et al.   JOURNAL OF CHROMATOGRAPHY A

Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds

(2012) A. Palmeira et al.   CURRENT MEDICINAL CHEMISTRY

Diagnosing the decline in pharmaceutical R&D efficiency

(2012) Jack W. Scannell et al.   NATURE REVIEWS DRUG DISCOVERY

The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma

(2010) P. A. Spagnuolo et al.   BLOOD